LATEST NEWS

ANVISA updates the resolution for Brazilian Good Manufacturing Practices Certification granting and renewal

Date: 06/22/2022

Resolution RDC 687/2022 was published on May 18th in the Federal Official Gazette. The new resolution provides for the criteria for granting or renewing the Brazilian Good Manufacturing Practices Certification for medical devices, and came into force on June 1st 2022, revoking RDC 183/2017.

RDC 687/2022 applies to risk class III and IV medical devices’ manufacturing units producing final products on their behalf or for other companies (including Software as a Medical Device – SaMD), or that carry out final releases of final products and that are involved in at least on stage of production other than design, distribution, sterilization, packaging or labeling stages.

Check the main changes when comparing to the previous resolution:

• Extends the scope of the resolution to all national and international establishments, no longer being restricted to establishments located outside of the national territory and Mercosur.

• Includes the mandatory certification for manufacturing units with packaging activities considered as a sterile barrier system for products declared as sterile, as well as manufacturing units of medical devices for in vitro diagnostics that perform the steps of impregnation, immunochromatography lamination or strip cutting.

• Updates the list of documents required for BGMP petition of granting and renewal processes.

• Accepts inspection reports issued by auditing bodies within the scope of a specific audit program recognized by ANVISA which were issued up to 3 years before the protocol date.

• Establishes that, in case of non-conformities listed in the audit report, an action plan must be forwarded to ANVISA and – if the non-conformity is still open – a request to comply with additional requirements will be issued.

• Certificates issued based on documentation analysis will not exempt the company from receiving on-site inspection by ANVISA, at any time. Refusal to receive the inspection or requests to change dates not accepted by ANVISA results in cancellation of the BGMP Certificate.

• Establishes a maximum period of 180 (one hundred and eighty) days for new manufacturing units within the scope of the new Resolution to apply a request for BGMP Certification.

Manufacturers must submit the following documents to request a BGMP Certificate:

To renew the BGMP Certificate, it is necessary to present the application Form as well as inspection and audit reports carried out. The other documents are necessary only in case it is necessary to update the information previously presented.

The resolution RDC 687/2022 also mentions the publication of the Risk Matrix used for risk analysis which subsidizes the granting of the BGMP Certificate through documentary evaluation, allowing greater understanding of the evaluation criteria. The Matrix disclosed considers the result of documents’ evaluation, the complexity of the manufacturing unit, the technologies involved and the intrinsic risk of the devices and indication of use, amongst others.

Follow us on social media to get an update on the top news regarding the Brazilian regulatory system.

DOMO Salute Team

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]